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Abstract
A variety of genetic diseases in the retina, including retinitis pigmentosa and leber congenital amaurosis, might be excellent
targets for gene delivery as treatment. A major challenge in non-viral gene delivery remains finding a safe and effective
delivery system. Poly(beta-amino ester)s (PBAEs) have shown great potential as gene delivery reagents because they are
easily synthesized and they transfect a wide variety of cell types with high efficacy in vitro. We synthesized a combinatorial
library of PBAEs and evaluated them for transfection efficacy and toxicity in retinal pigment epithelial (ARPE-19) cells to
identify lead polymer structures and transfection formulations. Our optimal polymer (B5-S5-E7 at 60 w/w polymer:DNA
ratio) transfected ARPE-19 cells with 4465% transfection efficacy, significantly higher than with optimized formulations of
leading commercially available reagents Lipofectamine 2000 (2667%) and X-tremeGENE HP DNA (2266%); (p,0.001 for
both). Ten formulations exceeded 30% transfection efficacy. This high non-viral efficacy was achieved with comparable
cytotoxicity (2366%) to controls; optimized formulations of Lipofectamine 2000 and X-tremeGENE HP DNA showed 1563%
and 3269% toxicity respectively (p.0.05 for both). Our optimal polymer was also significantly better than a gold standard
polymeric transfection reagent, branched 25 kDa polyethyleneimine (PEI), which achieved only 861% transfection efficacy
with 2566% cytotoxicity. Subretinal injections using lyophilized GFP-PBAE nanoparticles resulted in 1.161610
3-fold and
1.560.7610
3-fold increased GFP expression in the retinal pigment epithelium (RPE)/choroid and neural retina respectively,
compared to injection of DNA alone (p=0.003 for RPE/choroid, p,0.001 for neural retina). The successful transfection of the
RPE in vivo suggests that these nanoparticles could be used to study a number of genetic diseases in the laboratory with the
potential to treat debilitating eye diseases.
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Introduction
Many of the most debilitating ocular diseases are caused by gene
deletion mutations. The ability of an ocular disease to be treated
with a single gene replacement therapy was shown to be successful
in principle in a canine model of Leber’s Congenital Amaurosis in
which RPE 65 was replaced using a recombinant adeno associated
viral (AAV) delivery system that resulted in visual restoration in
these animals [1]. Furthermore, early phase clinical trials studying
this therapy in people suggest that gene therapy is a feasible
potential strategy for retinal dystrophies [2]. A variety of genetic
diseases of the retina, including retinitis pigmentosa, Best’s disease,
and Stargardt’s disease might be excellent targets for gene
replacement therapy.
Despite the initial success of gene replacement, gene delivery
methods need to be optimized. There are significant limitations to
viral delivery systems such as the AAV vector. The AAV vector is
limited in what ocular diseases it could potentially treat because it
is capable of optimally carrying 4.7–4.9 kilobases (kb) with a
maximum carrying capacity of 5.2 kb [3] while many ocular
diseases are caused by mutations to genes that are larger than
5 kb. Notable examples include Best’s disease, caused by a
mutation in Bestrophin-1 (14.6 kb) [4], or Stargardt’s disease,
caused by a mutation in the ABCA4 gene (6.8 kb) [5]. To address
this problem, we recently reported that our non-viral delivery
system using poly(beta-amino) esters (PBAEs) can accommodate
large inserts to deliver up to 100 plasmids and ,500 kbp of
nucleic acid per nanoparticle [6].
Non-viral systems for gene delivery offer a host of potential
advantages over viruses, including reduced toxicity [7], reduced
immunogenicity [8], and ease of production. However, to date,
most non-viral systems are significantly less efficient at transfecting
hard to transfect cell types compared to viral methods, so the
major challenge remains finding an effective non-viral delivery
system [9,10]. Multiple alternative non-viral gene delivery
approaches have been reported in the literature for in vitro
transfection of retinal pigment epithelial (RPE) cells, with limited
success. One report on transfection of the established RPE cell
line, ARPE-19 cells, with solid lipid nanoparticles details difficulty
in uptake of the particles that resulted in a transfection efficacy of
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37543only 2.5% [11]. Another study looked at optimizing several
different commercially available reagents (Tfx-50, Lipofectin,
Lipofectamine, Cellfectin, and DMRIE-C) for the transfection of
primary RPE cells [12]. This study utilized serum free-conditions
and non-confluent RPE cultures, which are associated with higher
transfection efficacy [13], yet the best reagent formulated
optimally, Tfx-50 at 3:1 DNA:liposome ratio, only achieved 12–
15% transfection efficiency [12]. Another study looking at the
transfection of primary RPE cells showed transfection efficiencies
of less than 1% for Lipofectin, between 1 and 3% for DOTAP/
DOGS, and up to 5% by using degraded dendrimers [13]. This
limited success in transfection of ARPE-19 cells or primary RPE
cells in vitro indicates a need for improved transfection reagents for
use in the lab.
Poly(beta-amino) esters (PBAEs) [14] have shown great potential
as gene delivery reagents and are easily synthesized, rapidly
screened, and can be transfected into a wide variety of cell types
with high efficacy in vitro [15,16,17,18,19]. PBAE nanoparticles
have several advantages which help to overcome the barriers to
intracellular plasmid DNA (pDNA) delivery [10]. PBAEs, when
added to pH 5 buffer, are positively charged and can spontane-
ously form positively-charged nanoparticles (generally less than
200 nm) when added to negatively charged pDNA [6]. They get
taken up via endocytosis, and enable endosomal escape by
buffering the endosome [20]. They are degraded by hydrolysis
of the ester bonds in the polymer backbone, enabling reduced
cytotoxicity when compared to non-degradable controls [14].
Previous studies have indicated that not only was the base polymer
important to its gene delivery properties, but that modification of
the polymer ends can further improve transfection efficiency
[15,16,17,20]. We have recently found that PBAEs are highly
effective (65%–85%) for the transfection of human macrovascular
cells (human umbilical vein endothelial cells) and human
microvascular cells (human retinal endothelial cells) and that
although the efficacies of these nanoparticles are highly correlated
between human vascular cell types, their efficacies are uncorre-
lated to human retinal pigment epithelial cells, which are also a
more difficult cell type to transfect [21].
In this study, we synthesized and evaluated an expanded
combinatorial library of PBAEs for evaluation of transfection
efficacy and toxicity in ARPE-19 cells to identify lead polymer
structures and transfection formulations for this difficult-to-
transfect cell type. We discovered a lead polymer, polymer (1-(3-
aminopropyl)-4-methylpiperazine-end-modified poly(1,5 pentane-
diol diacrylate-co-5-amino-1-pentanol) (B5-S5-E7) and character-
ized it for the first time in terms of polymer molecular weight,
polymer half-life, nanoparticle size, nanoparticle zeta potential,
and vitro efficacy compared to leading commercially available
reagents. To validate the in vitro screen and to evaluate the efficacy
of a PBAE-based nanoparticle for gene delivery to the eye for the
first time, nanoparticles were administered to mouse RPE in vivo by
subretinal injection. Lyophilized DNA nanoparticles, utilizing a
technology designed to enhance the stability and shelf-life of the
biodegradable nanoparticles, were used for the in vivo injections.
Figure 1. Schematic showing polymerization scheme and monomers used. (A) Diacrylates (‘‘B’’) were added to primary-amine containing
amino-alcohol side chains (‘‘S’’) to form the base polymers. (B) Base polymers were end-capped with amine monomers (‘‘E’’) to form the final, end-
modified polymers. (C) The base diacrylate (‘‘B’’), amino-alcohol side chain (‘‘S’’), and end-modifying amines (‘‘E’’) used in the polymer library are listed
here. (D) The full structure of B5-S5-E7 (1-(3-aminopropyl)-4-methylpiperazine-end-modified poly(1,5 pentanediol diacrylate-co-5-amino-1-pentanol)
is shown here.
doi:10.1371/journal.pone.0037543.g001
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diseases in the laboratory and as a potential treatment modality.
Materials and Methods
Materials
All reagents and solvents were obtained from commercial
suppliers and used as received. Monomers were purchased from
Acros Organics, Alfa Aesar, Fluka, Monomer-Polymer and Dajac
Laboratories, Sigma-Aldrich, and TCI America. CMV-eGFP was
amplified by Aldevron (Fargo, ND). X-tremeGENE HP DNA,
Lipofectamine 2000, and Opti-MEM I were purchased from
Invitrogen and used according to the manufacturer’s instructions.
25 kDa PEI was purchase from Sigma Aldrich and diluted to a
stock solution at 1 mg/ml in deionized water. 96 AQueous One
MTS assay was purchased from Promega and used according to
the manufacturer’s instructions. Dulbecco’s Modified Eagle
Medium (DMEM) F12 was purchased from Invitrogen and
supplemented with 10% fetal bovine serum (FBS; Invitrogen).
Polymer Synthesis
End-modified PBAEs were synthesized in a two-step process,
first by synthesizing the base polymer via Michael addition of
primary amines to diacrylates (Figure 1A). The library of PBAEs
was synthesized by adding primary amines to diacrylate
compounds (1.2:1 molar ratio of diacrylate:amine) at 90uC for
24 h (Figure 1A). The base polymerization reaction was
performed without the use of any solvent in 20 mL glass
scintillation vials, in an oven in the dark under magnetic stirring.
By providing excess diacrylate in the initial polymerization
reaction, diacrylate-terminated polymer was synthesized. We have
recently described the synthesis and characterization of these
materials [17]. The naming convention used here is designed to
describe the chemical structure of each polymer. The diacrylates
form the base (‘‘B’’) chain of the polymer, and the primary amines
form the side (‘‘S’’) chains of the forming polymer. To further
identify the structure of the base or side chain, a number
corresponding to the number of carbons in the hydrocarbon
portion of the ‘‘B’’ or ‘‘S’’ is appended; thus, B5 is a base diacrylate
with 5 carbons in it’s hydrocarbon portion between acrylate
groups, and B5-S5 is a base polymer with 5 carbons in the
Figure 2. Bar graph displaying confluent ARPE-19 cell-sheet
transfection efficacy (%GFP+ cells by FACS) of polymer
formulations (n=4) in our library screen. (A) Transfection efficacy
of polymer library formulated at 30 w/w ratio. (B) Transfection efficacy
of polymer library formulated at 60 w/w ratio. Optimal formulation B5-
S5-E7 at 60 w/w resulted in 44% transfection efficacy as compared to
26% for Lipofectamine 2000, 22% for ExtremeGENE HP DNA, and 8% for
branched 25 kDa PEI.
doi:10.1371/journal.pone.0037543.g002
Figure 3. Comparison of base polymer structure with transfec-
tion efficacy. Each bar represents the average transfection efficacy
associated with the end-modified polymers that contained the base
polymer shown (n=11; error bar=SEM). Base diacrylate and side chain
amino-alcohols are shown from least hydrophobic to most hydrophobic
from left to right. (A) Transfection efficacy of 30 w/w formulations
averaged over 11 end-modified amines containing the base polymer
shown. (B) Transfection efficacy of 60 w/w formulations averaged over
11 end-modified amines containing the base polymer shown. For
statistical analysis, see Table 1.
doi:10.1371/journal.pone.0037543.g003
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37543hydrocarbon portion of its side chain between the amine and
alcohol groups as well as 5 carbons in its hydrocarbon portion of
its base chain between acrylate groups. In a second step, the
acrylate ends of the polymer intermediates are modified by a
second amine, resulting in the final end-modified polymers
(Figure 1B). The base polymers were end-capped by end-capping
(‘‘E’’) amines (at 10-fold molar excess of amine to diacrylate
termini) at room temperature in DMSO at 100 mg/ml for 1 hr
(Figure 1B). Specifically, 80 mg of base polymer was dissolved in
400 ml of DMSO, and combined with 320 ml of a 0.5 M solution
in DMSO of the end-capping amine, and placed on a multitube
vortexer (VWR) and vortexed for 1 hr at 1000 RPM. The library
of monomers used here is shown (Figure 1C). For the end
capping amines, the number is simply sequential; B5-S5-E7 is an
end-modified polymer with 5 carbons in the base, 5 carbons on the
side chain, and which was end-modified with the E7 end-capping
amine. For this study we synthesized a combinatorial library of
PBAEs using 5 diacrylates, 3 amino-alcohol side chains, and 11
end-modifying amines to form 165 end-modified polymers with
only small, single carbon changes to the backbone and side chains,
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Figure 4. Reduction in metabolic activity following PBAE
nanoparticle administration. Formulations plotted at 0% reduction
of metabolic activity here had equivalent or slightly higher metabolic
activity than untreated controls. (A) Reduction in metabolic activity post
transfection with polymer library formulated at 30 w/w ratio (n=4). (B)
Reduction in metabolic activity post transfection with polymer library
formulated at 60 w/w ratio (n=4).
doi:10.1371/journal.pone.0037543.g004
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polymerization of all base polymers and end-capping of one
base-polymer with all end-capping amines was verified by NMR;
for spectra, see [17].
In vitro Polymer Library and Commercial Control
Transfection Screening
ARPE-19 cells were maintained as previously described [22],
plated at 100,000 cells/cm
2 in 96-well plates, and allowed to grow
for 72 hr until visually confluent prior to transfection with
nanoparticles containing eGFP pDNA. To form the particles,
polymer stock solutions at 100 mg/ml in DMSO and pDNA stock
solutions at 1 mg/ml in water were separately dissolved in 25 mM
sodium acetate (NaAc) buffer at pH 5.0, then combined and
mixed by pipeting. Ten minutes later, 20 ml of particle solution
containing 600 ng pDNA and 36 mg polymer was added to 100 ml
of medium on the cells and allowed to incubate for 4 hr, when the
medium was then replaced with fresh medium. For the
commercially available lipid based controls Lipofectamine 2000
and X-tremeGENE HP DNA, reagents were formulated as
specified by the company (at 100 ng pDNA/well), and also tested
at the same DNA dose as used in our screening (600 ng/well) to
ensure that optimal, comparable controls were chosen. For PEI
transfection, a PEI stock solution at 1 mg/ml was diluted in Opti-
MEM I, and mixed with pDNA in Opti-MEM. The solution was
then vortexed and allowed to stand for 20 minutes before being
added to cells. 24 hr post-transfection, cell viability was analyzed
by the CellTiter 96H AQueous One MTS assay using a plate reader
(BioTekH Synergy 2), and is reported as a reduction in cell viability
relative to untreated wells (100% – absorbance of well/untreated,
normalized to no cells in the well). 48 hr post-transfection,
transfection efficacy was analyzed by flow cytometry (Accuri C6
with Hypercyte high-throughput plate adaptor).
Preparation of lyophilized nanoparticles
Freeze dried pDNA nanoparticles were prepared by dissolving
36 ml of 100 mg/ml polymer in DMSO in 324 mlo f2 5m M
sodium acetate buffer (pH 5.0), and then adding 60 ml of 1 mg/ml
pDNA (total 60 mg) with 60 ml of 25 mM sodium acetate buffer
(pH 5.0). The mixture was vortexed, and allowed to self-assemble
for 10 minutes. The nanoparticles were split into two batches and
Figure 5. Comparison of base polymer structure with reduction
in metabolic activity. Each bar represents the average toxicity
associated with the end-modified polymers that contained the base
polymer shown (n=11; error bar=SEM). Base diacrylate and side chain
amino-alcohols are shown from least hydrophobic to most hydrophobic
from left to right. (A) Reduction in metabolic activity of 30 w/w
formulations averaged over 10 end-modified amines containing the
base polymer shown. (B) Reduction in metabolic activity of 60 w/w
formulations averaged over 10 end-modified amines containing the
base polymer shown. For statistical analysis, see Table 1.
doi:10.1371/journal.pone.0037543.g005
Figure 6. Comparison to commercially available transfection
reagents. (XG HP=XtremeGENE HP; Lipo=Lipofectamine 2000;
PEI=25 kDa branched polyethyeleneimine). The numbers next to the
reagent name corresponds to the ratio of lipid (v/v) or polymer (w/w) to
DNA used. (A) Transfection efficacy of control formulations and B5-S5-
E7 at 60 w/w (n=4); * indicates p,0.001 vs. B5-S5-E7 at 60 w/w. (B)
Reduction of metabolic activity of control formulations and B5-S5-E7 at
60 w/w (n=4); # indicates p,0.05 vs. B5-S5-E7 at 60 w/w.
doi:10.1371/journal.pone.0037543.g006
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then flash-frozen in liquid nitrogen, and placed on a lyophilizer for
freeze-drying. The dried particles (containing 30 ml pDNA) were
then resuspended to 30 ml total volume in deionized water (thus
resulting in a particle DNA concentration of 1 mg/ml) just prior to
subretinal injection.
Particle Sizing and Zeta Potential measurements
Particle sizing was performed using a NanoSight NS500
(NanoSight Ltd. Wiltshire, UK). Each sample was diluted 1:50
from the transfection concentrations (n=3); for the lyophilized
samples, each sample was diluted to the same DNA concentration
as the freshly prepared samples. For zeta potential measurements,
800 microliters of particle solution containing 5 micrograms of
pDNA was diluted into PBS to a total volume of 800 ml and added
to a disposable zeta cuvette, and measured in using a Malvern
Zetasizer NanoZS.
Polymer Degradation
250 ml of a 100 mg/ml solution of B5-S5-E7 in DMSO was
added to 250 mL of phosphate buffered saline (PBS) solution at
37uC. At each time point, 25 mL of this solution was removed and
frozen, then lyophilized to remove the water. This sample was
dissolved in a solution of 94% THF, 5% DMSO and 1%
piperidine, and organic phase permeation chromatography (GPC)
was performed using the same solvent as an eluent at a flow rate of
1 mL/minute. The detector (Waters 2414 refractive index
detector) and columns (three Waters Styragel columns, HR1,
HR3, and HR4, in series) were maintained at 40uC throughout
the runs. Polymer molecular weights presented are relative to
monodisperse polystyrene standards (Shodex, Japan).
Subretinal Injections
Subretinal injections were performed in both eyes of 3 month
old C57Bl6 mice using a Pico-Injector (PL1-100, Harvard
apparatus, Holliston, MA). Mice were anesthetized by intramus-
cular (IM) injection of Ketamine (80 mg/kg)/Xylazine (16 mg/
kg). Pupils were dilated using 2.5% Phenylephrine Hydrochloride
Ophthalmic solution (AK-DILATE, Akorn, Lake Forest, IL)
followed by administration of 0.5% Tetracaine Hydrochloride
Ophthalmic solution (Phoenix Pharmaceutical Inc., St. Joseph,
MO) eye drops just before the injection. The conjunctiva adjacent
to the cornea was grasped with forceps to allow optimal exposure
of the injection site. A hole was made at the pars plana with the tip
Figure 7. Comparison of transfection efficacy to reduction in metabolic activity of the polymers in the polymer library. There is an
overall trend of increasing cytotoxicity with increasing transfection efficiency (the best-fit line represents a 0.77% decrease in cell metabolic activity
with every 1% increase in transfection efficiency of the formulation) but the trend only explains a portion of the results (R
2=0.37). A number of
polymer formulations exhibited high transfection efficiencies and low concomitant cytotoxicities.
doi:10.1371/journal.pone.0037543.g007
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micropipette glass needle tip mounted on a Pico-Injector holder
was inserted in the hole, through the vitreous, and into the
potential subretinal space. One ml of PBAE nanoparticles with
eGFP pDNA and/or naked eGFP pDNA (at 1 mg/ml DNA, as
described above in ‘‘Preparation of lyophilized nanoparticles’’) was
then delivered. The retinal area injected was visualized as a retinal
bleb or a slight retinal detachment. Subretinal injections were
made under direct observation aided by a Zeiss dissecting
microscope at 66magnification. Immediately following injection
of the nanoparticles, a small amount of Bacitracin Zinc and
Polymyxin B Sulfate Ophthalmic ointment (Akorn, Buffalo Grove,
IL) was applied to the eye. Mice were sacrificed 72 hr later with
ether and cervical dislocation. Eyes were enucleated, and the
cornea and lens were removed. The retina and RPE/choroid were
dissected and prepared for RNA extraction. The fellow eye was
prepared for flat mount using confocal microscopy. Fluorescence
intensity was analyzed with ImagePro software. The eyes with
surgical complications were excluded from the study.
Statistical Analysis
GraphPad Prism 5 software was used for all statistical analysis.
For comparison of best polymer formulation (B5-S5-E7 at 60 w/w)
with commercially available controls with respect to transfection
and reduction in cell metabolic activity, we performed a 1-way
ANOVA with a Dunnet post-test using B5-S5-E7 at 60 w/w as the
control column. For comparison of base polymer structural effects
with respect to transfection and reduction in cell metabolic
activity, we performed a 2-way ANOVA with a Bonferroni post-
test to compare all columns to each other. A two-tailed unpaired
Student’s t-test was used for comparison of mRNA expression after
subretinal injection of nanoparticles versus pDNA alone.
Results
Transfection efficacy and cytotoxicity in ARPE-19 cells: The transfec-
tion efficacy of the nanoparticle formulations (30 and 60 w/w
polymer:DNA ratio, 600 ng/well DNA dose in a 96 well plate)
ranged from 0–44% GFP+ cells (Figure 2), with only small, single
carbon changes to the backbone of the polymer structure or small
changes to the ends of the polymers. To look at the effects of single
carbon changes along the base polymer with respect to transfec-
tion efficacy, we averaged across the various end-modified versions
Figure 8. Number-averaged molecular weight versus time of B5-S5-E7 in PBS at 376C with agitation. The half-life of the polymer in
solution was 4.6 hr (R
2=0.984), and the polymer was almost completely degraded within 1 day.
doi:10.1371/journal.pone.0037543.g008
Figure 9. Biophysical characterization of nanoparticles before
and after lyophilization. (A) Hydrodynamic diameter of freshly
prepared DNA/B5-S5-E7 particles versus lyophilized particles (n=3; bars
are standard error). (B) Zeta potential of freshly prepared DNA/B5-S5-E7
particles versus lyophilized particles (n=3; bars are standard error).
Differences in particle size (p=1) and zeta potential (p=0.05) are not
significant.
doi:10.1371/journal.pone.0037543.g009
Polymer Nanoparticles for Transfection
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ANOVA to examine the trends statistically (Table 1). Generally,
transfection efficacy tended to increase with increasing hydropho-
bicity of the diacrylate or side chain in the base polymer.
Interestingly, for the least hydrophobic backbones (B3b, B4) the
biggest changes (and the only statistically significant ones) with
respect to transfection efficacy occurred when increasing the side
chain hydrocarbon length from 3 to 4 carbons, whereas with the
more hydrophobic backbones (B5, B6), the only statistically
significant increases in transfection efficacy occurred when
increasing the side chain hydrocarbon length from 4 to 5 carbons.
Only intermediately hydrophobic base diacrylates B4 and B5
showed strong statistically significant improvements when increas-
ing the side chain length from 3 to 5 carbons.
The vast majority of the nanoparticle formulations showed only
small reductions in cell metabolic activity compared to untreated
controls (Figure 4), with the exception of some of the B6-S4, B6-
S5 and E9-end modified polymers. To look at the effects of single
carbon changes along the base polymer with respect to cell
cytotoxicity, we averaged across the various end-modified versions
of the same base polymer (Figure 5) and performed a 2-way
ANOVA to examine the trends statistically (Table 1). Cytotox-
icity, like transfection efficacy, also tended to increase with
increasing hydrophobicity of the diacrylate or side chain in the
base polymer (Figure 5). There was increased cytotoxicity with
Figure 10. Confocal image of RPE/choroid flat mount post subretinal injections; green corresponds to fluorescence due to GFP
expression. Both images were taken with the same camera settings. (A) pDNA alone. (B) pDNA/nanoparticle injection. (C) Relative transcript level to
GAPDH (set at 10,000) of GFP mRNA expression after subretinal injection of PBAE eGFP nanoparticles and subretinal injection of naked DNA. Each
injection is diplayed as a separate point, and the mean relative transcript level is displayed as a bar. Subretinal injections using lyophilized GFP-PBAE
nanoparticles resulted in 1.161610
3-fold and 1.560.7610
3-fold increased GFP expression in the RPE/choroid and neural retina, respectively,
compared to injection of DNA alone (p=0.003 for RPE/choroid, p,0.001 for neural retina). (D) Relative fluorescence intensity of retinal flat mounts
after subretinal injection with GFP nanoparticles and GFP plasmid alone (n=3).
doi:10.1371/journal.pone.0037543.g010
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B3, B4, B5 and B6) as compared to the least hydrophobic side
chain S3. Interestingly, The least hydrophobic backbones (B3,
B3b) only showed increased cytotoxicity when the side chain
length increased from 4 to 5 carbons and not from 3 to 4 carbons
at 60 w/w, whereas the more hydrophobic backbones (B4, B5, and
B6) showed increased cytotoxicity when the side chain length
increased from 3 to 4 carbons (p,0.01 for all 3), but no significant
increase in cytotoxicity with side chain length increasing from 4 to
5 carbons. Cytotoxicity also increased with increasing hydropho-
bicity of the base diacrylate, although there seems to be no
increase in toxicity when the backbone contains 4 carbons (B4)
between diacrylate groups as compared to only 3 (B3).
The formulation with the highest transfection efficacy was B5-
S5-E7 at 60 w/w polymer:DNA (4465%), and it was also
relatively non-toxic (23% cell cytotoxicity) following transfection.
This is significantly higher transfection than has been previously
reported in the literature [11,12,13], and was significantly higher
than optimized formulations of FuGeneHD (Roche) or Lipofecta-
mine 2000 (Invitrogen), two of the leading commercially available,
cationic lipid based transfection reagents, or 25 kDa branched
polyethyleneimine (Figure 6). Lipofectamine 2000 was optimal at
a 600 ng pDNA dose with a 4 to 1 ratio of lipid:DNA and enabled
2667% transfection and 1663% toxicity. X-tremeGENE HP
DNA was optimal at a 600 ng DNA dose with a 5 to 1 ratio of
lipid:DNA, yielding 2266% transfection and 3269% toxicity.
Branched 25 kDa polyethyleneimine (PEI) performed optimally at
a 3:1 ratio at 600 ng DNA/well, only achieving 861%
transfection efficacy with 2566% toxicity. A 1-way ANOVA with
a Dunnet post-test with B5-S5-E7 as the control column showed
that B5-S5-E7 at 60 w/w was significantly more efficacious than
any of the positive controls (p,0.001) but maintained comparable
cell viability (p.0.05 for all controls at 600 ng/well except for
Lipofectamine 200 at a ratio of 2:1).
In general, increased transfection brought with it concomitant
increased cytotoxicity (Figure 7), but many formulations were
either ineffective but moderately toxic or effective but fairly non-
toxic. In general, among the base polymers which enabled high
transfection, polymers containing B3-S5 were on the ‘‘bad’’ side of
the best fit line (higher cytotoxicity relative to their transfection)
and B4-S5 containing polymers were on the ‘‘good’’ side of the
best fit line (lower cytotoxicity relative to their transfection). This
can also vary by end group – B5-S5-E7 achieved the highest
transfection efficacy (4465%) with relatively low cytotoxicity
(2366%), but B5-S5-E4, with the same base polymer but different
end group, transfected only 22% of cells with 39% cytotoxicity.
Nanoparticle Physical Characterization: Our lead polymer from the in
vitro study, B5-S5-E7, when prepared in a large batch and purified,
is moderately polydisperse, with a polydispersity index of 3.2, a
number averaged molecular weight of 25,000 Da, and a weight-
averaged molecular weight of 80,000 Da. It is hydrolytically
degradable, with a free polymer half-life of 4.6 hr in physiological
salt solution at 37uC( Figure 8). When complexed with pDNA, it
forms nanoscale particles (hydrodynamic diameter of 180 nm),
which are positively charged (zeta potential of +26 mV). The
particles, when lyophilized, retain these characteristics, showing
very comparable zeta potential and particle size after undergoing
the freeze-drying process and being resuspended (Figure 9).
Subretinal Injection of Lyophilized GFP-Nanoparticles: A successful
subretinal injection caused a bleb or retinal detachment of
approximately 1/8 to 1/4 of the retina. Subretinal injection
(n=5) of 1 ml of 1 mg/ml lyophilized pDNA nanoparticles (60 w/
w B5-S5-E7:DNA) resulted in significant transfection in the area of
injection (Figure 10B), and quantitatively increased by over
1000-fold the expression of GFP mRNA by RT-PCR in both the
retina (p,0.001) and the RPE/choroid (p=0.003; Figure 10C)
72 hr post injection as compared to control subretinal injections of
pDNA alone (n=5 for nanoparticle groups, n=3 for controls). In
an absolute sense, nanoparticle injection increased GFP mRNA
transcript levels to about K that of GAPDH. Intensity data from
florescence micrographs (n=3) showed increased fluorescence in 2
of 3 of the RPE flat mounts which were exposed to the
nanoparticles, but in aggregate the difference was not statistically
significant compared to injection of pDNA alone (p=0.08;
Figure 10D).
Discussion
Standard non-viral transfection protocols for in vitro transfection
of RPE cells achieve only limited to moderate success in terms of
transfection efficiency. In addition, unlike typically optimal in vitro
transfection conditions, where the transfection is done without
serum and with cells in a sub-confluent state to maximize
transfection, in vitro conditions were chosen here to more closely
match the in vivo state. As RPE cells in the mature eye are not
rapidly dividing and particles will come into contact with proteins
before reaching cell surfaces, we used confluent cells in the
presence of serum for our in vitro studies.
Figures 2–6 show interesting trends to guide the design of
polymeric nanoparticles for transfection of retinal pigment
epithelial cells. As seen previously in studies looking at transfection
of COS-7 monkey kidney cancer cells [17], we can see interplay
between the hydrophobicity of the base diacrylates and the side
chain amino-alcohols (for statistical analysis, see Table 1). For
example, relatively hydrophilic base polymers containing the
shortest side chain, S3, were generally ineffective, and required the
most hydrophobic base diacrylates, B5 and B6, to see any
transfection efficacy. They were also non-toxic. On the other
hand, polymers containing the most hydrophobic side chain, S5,
were nearly all reasonably effective in transfection. Optimal
transfection for many end-groups was achieved with the interme-
diately-hydrophobic base-diacrylates B4 and B5 and most
hydrophobic side chain S5. End-modified polymers with the most
hydrophobic base group (B6) did not tend to be as effective and
also were associated with more cytotoxicity, and B3-S5 end-
modified polymers were not as efficacious but were non-toxic.
Interestingly, increasing the hydrophobicity of the side chain from
3 to 4 carbons in length tended to increase the transfection efficacy
of polymers containing the least hydrophobic base diacrylates
without increasing the cytotoxicity, whereas increasing the side
chain length from 4 carbons to 5 carbons for the most
hydrophobic base diacrylate only increased the cytotoxicity of
the formulation without increasing transfection efficacy. Taking
this together suggests that polymer hydrophobicity plays a key role
in the transfection efficacy of these complexes, but that there is a
limit at which polymer hydrophobicity no longer increases
transfection efficacy as fast as it increases cytotoxicity, such that
there is an optimal hydrophobicity for PBAE based non-viral gene
delivery vectors.
End-modification of the polymers had a clear and strong effect,
with polymers end-modified with E1 and E3-E8 tending to be
more successful, and polymers modified with E9, E10, and E12
end-modifications tending to be less effective. Increasing polymer
to pDNA weight ratio from 30 w/w to 60 w/w tended to both
increase transfection efficacy and cytotoxicity; however, even at 60
w/w the cytotoxicity was moderate for most transfection
conditions. Molecular weight was previously found to not vary
the transfection efficacy of these materials [17], so that these
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chemical structure that we observe. These small changes in
structure may play a role in changing the DNA/polymer binding
properties, changing the particle size, and changing the degrada-
tion rate of the nanoparticles, all of which could play a significant
role in the observed gene delivery properties of the polymer
library.
We next sought to test the most successful type of nanoparticle
in vivo. However, in vivo injections into the eye require low volumes
and highly concentrated pDNA nanoparticles. The maximum
volume that can be injected into the mouse eye is 1 mL. Simply
scaling down our transfection protocol to the 1 ml volume required
for the subretinal injections would have allowed us to deliver only
30 ng of DNA to the eye. Due to the hydrophobicity of the
polymers, formulation of particles at greater than 30-fold higher
concentration (which would be required for our desired 1 mg dose
to the eye) in standard aqueous conditions is not possible due to
polymer solubility constraints. However, our lab has recently
developed a protocol to formulate PBAE-based nanoparticles by
adding sucrose as a cryoprotectant and then freeze-drying the
particles. This process has been shown to allow long-term storage
of the particles, with complete retention of transfection efficiency
in glioblastoma cells after 3 months [18]. Although in vitro
transfection efficacy has been validated using this procedure, in vivo
efficacy of these lyophilized PBAE nanoparticles is unknown. Since
the dry polymer/DNA nanoparticles can be resuspended following
lyophilization in minimal water volumes, we hypothesized that we
could increase nanoparticle concentration using this procedure.
This is likely because resuspension of the nanoparticles requires
formation of a colloidal suspension of polymer/DNA nanoparti-
cles and does not require solvation of free polymer at the same
concentrations. The cryoprotectant is also required for this step, as
particles formed without cryoprotectant were unable to be
resuspended. We were able to formulate 60 w/w particles with
30 mg of pDNA, add sucrose, freeze dry the particles, and then
resuspend the particles to 30 ml total volume in water, thus
allowing the injection of 1 mg of DNA in 1 ml. This technique has
several advantages beyond simply increasing the concentration of
the particles, such as easy storage and low risk of degradation.
Significant transfection of the RPE and retina was achieved with
subretinal injection of 1 ml of 1 mg/ml DNA nanoparticles, in the
area of injection (Figure 9B). Quantitatively, there was over
1000-fold increase in expression of GFP mRNA by RT-PCR in
both the retina and the RPE/choroid (Figure 9C). The relative
expression of GFP mRNA varied between the different mice (86–
3800 fold increase in the retina, and 50–5000 fold increase in the
RPE/choroid), compared to naked eGFP DNA injection. None-
theless even the lowest transfection is significantly higher than
other delivery systems. A recent article by Muna Naash’s
laboratory studied CK30PEG10k complexed with eGFP to
transfect RPE and found a 2.5 fold increase in eGFP expression
in the RPE compared to a naked pDNA control [23].
Interestingly, they found similar uptake of GFP with
CK30PEG10k as with naked GFP due to the RPE cell’s ability
to phagocytoze naked GFP, and attributed their 2.5-fold
improvement in transfection to improvements in downstream
nuclear import [23]. Here, we are able to show a .1000-fold
increase in GFP expression in the retina and RPE with our
nanoparticles, which are specifically designed for improved
intracellular delivery. PBAE nanoparticles are believed to improve
intracellular delivery by binding and protecting pDNA, and
facilitating both endosomal escape and the release of the DNA to
the cytoplasm [20].
Here we show that poly(beta-amino) ester-based nanoparticles
have great promise for delivery of plasmids to RPE cells. These
nanoparticles are small in size (180 nm), have a positive zeta
potential (+26 mV), and easily degrade in water. Many polymer
formulations showed transfection efficacy that was significantly
superior to Lipofectamine 2000 and FuGeneHD, two of the lead
commercially available alternatives for non-viral gene delivery,
with comparable cellular viability. The lead polymer, 1-(3-
aminopropyl)-4-methylpiperazine-end-modified poly(1,5 pentane-
diol diacrylate-co-5-amino-1-pentanol) (B5-S5-E7), at 60 w/w
polymer:DNA ratio was able in vitro to transfect 44% of ARPE-19
cells that were visually confluent with minimal cytotoxicity.
Therefore, this novel nanoparticle has many potential benefits to
further investigate ocular diseases. The successful transfection of
the RPE in vivo with lyophilized nanoparticles using this polymer
formulation suggests that this technology could be useful in the
future in vivo both in the lab and possibly in the clinic, to help
ameliorate genetic diseases of the retina.
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